Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.

Summary

In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.

Eligibility

Inclusion criteria：

* Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology and with advanced or metastatic disease that cannot be resected
* HER2 negative
* Not received any anti-tumor treatment before.
* After evaluation, the treatment plan is chemotherapy combined with immunotherapy.
* Aged 18 to 75 years old, gender is not limited.
* Expected survival time is greater than or equal to 3 months. Exclusion criteria：
* Patients with malignant tumors other than gastric cancer or those with tumors metastasized to the stomach from other sites.
* Patients who have previously received anti-tumor treatments such as surgery, radiotherapy and chemotherapy, targeted therapy or immunotherapy.
* Patients with severe infections.
* Those with a history of mental illness cannot cooperate with the research.
* Patients with severe heart, liver, kidney and other diseases.
* Pregnant or lactating patients.
* HER2 positive.

Conditions3

Browse More Trials